Programmed cell death, a physiologic process for removing cells, is critically important in normal development and for elimination of damaged cells. Conversely, unattended cell death contributes to a variety of human disease pathogenesis. Thus, precise understanding of molecular mechanisms underlying control of cell death is important and relevant to public health. Recent studies emphasize that transforming growth factor-b-activated kinase 1 (TAK1) is a central regulator of cell death and is activated through a diverse set of intra-and extracellular stimuli. The physiologic importance of TAK1 and TAK1-binding proteins in cell survival and death has been demonstrated using a number of genetically engineered mice. These studies uncover an indispensable role of TAK1 and its binding proteins for maintenance of cell viability and tissue homeostasis in a variety of organs. TAK1 is known to control cell viability and inflammation through activating downstream effectors such as NF-jB and mitogen-activated protein kinases (MAPKs). It is also emerging that TAK1 regulates cell survival not solely through NF-jB but also through NF-jB-independent pathways such as oxidative stress and receptor-interacting protein kinase 1 (RIPK1) kinase activity-dependent pathway. Moreover, recent studies have identified TAK1's seemingly paradoxical role to induce programmed necrosis, also referred to as necroptosis. This review summarizes the consequences of TAK1 deficiency in different cell and tissue types from the perspective of cell death and also focuses on the mechanism by which TAK1 complex inhibits or promotes programmed cell death. This review serves to synthesize our current understanding of TAK1 in cell survival and death to identify promising directions for future research and TAK1's potential relevance to human disease pathogenesis.
the signal-transduction pathway leading to cellular responses. TAK1 has a powerful prosurvival role in activating the Ikb kinase (IKK)-NF-kB pathway, which has a number of target genes, many of which block apoptosis, promote cell proliferation and stimulate inflammatory responses. [1] [2] [3] Loss of TAK1 sensitizes cells to death through many of the myriad pathways known to activate TAK1, including TNFa. However, accumulating results suggest that TAK1 is essential for cell survival, above and beyond its role in NF-kB activation through pathways that are discussed in this review. Furthermore, despite TAK1's prosurvival function, TAK1 has also been found to participate actively in the RIPK1-and RIPK3-mediated necroptosis pathway under some circumstances. The story of TAK1 in maintaining and disrupting life leads to the conceptual synthesis of TAK1 as a regulator of cell fate. This review discusses the role of TAK1 signaling in cell death by incorporating TAK1's multiple paths to cell survival and cell death. Control of survival and cell death may allow us to target specific cells, such as tumor cells, for particular types of cell death.
TAK1 Activation and Downstream Pathways
The kinase TAK1 was first identified as a mitogen-activated protein kinase kinase kinase (MAP3K) and found to be activated by TGFb and bone morphologic protein. 4 Since this original finding, TAK1 also has been shown to be activated by a number of signaling molecules including cytokines such as TNFa and IL-1; ligands that interact with Toll-like receptors, B-cell receptor and T-cell receptor; and the lipotoxic molecule, ceramide. [5] [6] [7] [8] [9] [10] [11] [12] [13] Other endogenous death ligands of the TNF family, including TRAIL, also induce TAK1 activation. 14, 15 Exogenous stressors and environmental changes such as osmotic stress, UV irradiation, ischemia and nutrient withdrawal activate TAK1. 13, 14, 16, 17 Among these stimuli, the mechanism of TAK1 activation and its role in the TNFa signaling pathway has been extensively studied. Upon TNFa stimulation, adaptor molecules including TNFa receptor type-1-associated death domain protein (TRADD), TNFa receptorassociated factor 2 and 5 (TRAF2 and TRAF5), cellular inhibitor of apoptosis 1 and 2 (cIAP1/2) and RIPK1 are recruited to the receptor complex (TNF receptor 1 (TNFR1) Complex I) (Figure 1 ), in which RIPK1 acquires a K63-linked or linear polyubiquitin chain by E3 ligases, TRAF2/5 cIAP1/2 or linear ubiquitin chain assembly complex containing two E3 ligases HOIL-1 and HOIP. [18] [19] [20] [21] [22] TAK1 is recruited and activated through TAK1-binding protein 2 (TAB2) binding to the RIPK1 polyubiquitin chain. 23, 24 Upon binding the polyubiquitin chain, TAK1 phosphorylates and activates the IKK complex composed of IKKa, IKKb and NEMO (also called IKKg), which leads to phosphorylation and degradation of IkB resulting in activation of NF-kB ( Figure 1 ). Activated TAK1 also phosphorylates and activates MAPKKs leading to activation of MAPKs such as ERK, p38 and JNK ( Figure 1) . 6, 25 NF-kB and MAPKs induce downstream expression of inflammatory cytokines and antiapoptotic proteins such as cellular FLICE-like inhibitory protein (c-FLIP) and cIAPs. 26, 27 Drawing a link between TAK1 signaling and metabolism, studies have found that starvation and TRAIL induce autophagy in which TAK1 is actively involved by activating AMP-activated protein kinase and IKKs. 14, 17, 28, 29 In summary, TAK1 responds to exogenous stress conditions through a variety of mechanisms including TNFa family Figure 1 TNFa induces cell survival, apoptosis and necroptosis. Upon TNFa stimulation, TNFR1 forms Complex I, in which RIPK1 acquires a polyubiquitin chain. [18] [19] [20] [21] TAK1 binds to the polyubiquitin chain though TAB2, and activates the IKK complex, leading to the activation of NF-kB. TAK1 also activates MAPK cascades. 6, 25 NF-kB and MAPKs induce expression of inflammatory cytokines and antiapoptotic proteins. 26, 27 After Complex I formation, under some circumstances, the complex dissociates from TNFR1, leading to the formation of cytosolic protein complex known as Complex IIa composed of TRADD, FADD, RIPK1 and caspase-8. 43 Caspase-8 activation initiates a caspase cascade, which leads to apoptotic cell death. 44 If caspase-8 is inhibited, Complex IIb which include FADD, RIPK1 and RIPK3 is formed. 45 RIPK1-RIPK3 executes necroptosis through downstream molecule such as MLKL [46] [47] [48] TAK1 control of cell death SR Mihaly et al receptors, and activates cellular processes to mitigate stress conditions through intracellular signaling pathways including, but not limited to, IKK-NF-kB and MAPK pathways ( Figure 1 ).
The Roles of TAK1-Binding Proteins in TAK1 Activation
TAK1 forms complexes with its binding proteins TAB1, TAB2 and TAB3. [30] [31] [32] TAB2 and TAB3 are close homologs, whereas TAB1 is structurally unrelated to TAB2 or TAB3. TAB1 and TAB2/TAB3 bind to the N-terminal kinase domain and the C-terminal region of TAK1, respectively. TAB1 mediates oligomerization, autophosphorylation and activation of TAK1. 16, 33, 34 TAB1 is essential for TAK1 activation in response to osmotic stress but dispensable for cytokinemediated TAK1 activation. 16 O-linked glycosylation of TAB1 on S395 is implicated in activation of TAK1 activation in response to osmotic stress. 35 In contrast, TAB2 and its analogous protein TAB3 have been shown to have an important role in activation of TAK1 in cytokine signaling. TAB2 and TAB3 each have Np14 zinc-finger domain, which is necessary for recruitment of TAK1 to the RIPK1 polyubiquitin chain in the TNFa signaling pathway (Figure 1 ). 18, 24 Consistently, inhibition of TAB2 reduces TAK1 activity in several tissues and cell types. 32, 36, 37 However, Broglie et al.
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described that loss of Tab2 in dermal fibroblasts rather prolonged and increased the activation of TAK1 following TNFa stimulation. TAK1 is normally transiently activated by TNFa and deactivated by protein phosphatase 6 (PP6) 39 and protein phosphatase 2A. 40 TAB2 tethers the interaction between TAK1 and PP6 on the RIPK1 polyubiquitin chain in the TNFa signaling pathway, which may explain how TAB2 deficiency could lead to sustained activation of TAK1. In this context, activation of TAK1 may be compensated for by TAB3. While structurally very different, TAB1 and TAB2, at least in the epidermis, intestinal epithelium and differentiated macrophages have been shown to function redundantly to activate TAK1. 41, 42 As double deletion of Tab1 and Tab2 almost completely ablates TAK1 activity and phenocopies Tak1 deletion in the epidermis and intestinal epithelium, TAB3 does not appear to have a dominant role in TAK1 activation in these tissues. Further elucidation of the roles of these individual binding proteins requires more study, but it must be stressed that activation of TAK1 is regulated by TAB1, TAB2 and TAB3 in vivo, and their respective contributions are complex and depend upon tissue type and cellular context.
TAK1 Inhibits Apoptosis
When TAK1 is absent, cells are sensitive to cell death in response to several stressors. Among them, TAK1-regulated TNFa-induced cell death is well characterized. After TNFa receptor complex (Complex I) formation, under some circumstances, the TNFa-bound receptor complex dissociates from TNFR1, leading to molecular reorganization and the formation of a cytosolic death-inducing signaling complex including TRADD, FAS-associated protein with a death domain (FADD), RIPK1 and caspase-8, known as Complex IIa (Figure 1) . 43 In this complex, caspase-8 is dimerized, selfcleaved and activated to further activate downstream executioner caspases such as caspase-3, which leads to apoptotic cell death. 44 Moreover, if caspase-8 is perturbed by gene deletion or inhibited by a viral protein CrmA or by pharmacologic inhibitors, TNFa induces another shift of protein complexes toward Complex IIb that include FADD, RIPK1 and RIPK3 ( Figure 1) . 45 RIPK1-RIPK3 executes programmed necrosis, which is often called necroptosis, to induce an alternative cell death pathway when apoptosis fails. [46] [47] [48] Inhibition of TAK1 is usually followed by caspase-8 and -3 activation in response to TNFa, which suggests that TAK1 inhibits caspase activation cascade to block apoptotic cell death. 49 Thus, TAK1 is likely to blunt the formation or activation of Complex IIa. Recent studies revealed two major mechanisms through which TAK1 inhibits caspase activation ( Figure 2 ). TAK1-NF-kB pathway: TAK1 is a well-documented upstream kinase of NF-kB.
3,6,7 NF-kB transcriptionally upregulates antiapoptotic protein such as c-FLIP and IAP family proteins ( Figure 1 ). The IAP family includes cIAP1, cIAP2 and XIAP, which can inhibit caspase activation. 50 c-FLIP is structurally similar to caspases-8 but does not possess protease activity and forms a heterodimer with caspase-8, which competitively inhibits formation of highly active caspase-8 homodimer. 51, 52 We note here that c-FLIPcaspase-8 heterodimer still possesses limited proteolytic activity, 53, 54 which is important for cross-talk between apoptosis and necroptosis, as discussed later. Thus, it is feasible that TAK1 inhibits caspase activation through activation of NF-kB. However, it also suggests that an NF-kB-independent pathway is responsible for inhibition of apoptosis. In mouse models, Tak1 deletion causes more extensive cell death and tissue damage than ablation of NF-kB by deletion of IKKb or NEMO/IKKg (see Table 1 ). Intestinal epithelial-specific Tak1 gene deletion causes Figure 2 TAK1 protects cells from TNFa-induced apoptosis through two distinct pathways. TAK1 is an upstream kinase of NF-kB. 6 NF-kB transcriptionally upregulates antiapoptotic protein such as c-FLIP and IAP family proteins that inhibit caspase activation. 26, 27 In addition, TAK1 prevents TNFa-induced accumulation of ROS. ROS potentially cause depletion of cIAP proteins, 15 resulting in deubiquitination of RIPK1. This form of RIPK1 can activate caspase-8 in a kinase-dependent manner. 61 Thus, TAK1-NF-kB pathway and TAK1-dependent antioxidant pathway coordinately inhibit caspase activation and apoptotic cell death TAK1 control of cell death SR Mihaly et al TNFa-dependent tissue disruption from embryonic day 18.5, whereas ablation of IKKb or NEMO/IKKg does not cause significant cell death at early postnatal days. 55, 56 Hepatocyte-specific deletion of TAK1 triggers TNFa-dependent liver injury and hepatocellular carcinoma within 6 weeks of age, whereas loss of NF-kB activation by NEMO deletion causes much milder liver injury around 20 weeks of age. 57 Furthermore, it appears that NF-kB activity is not always regulated by TAK1 in some tissues in vivo. For example, Tak1 deletion in blood vessels leads to TNFa-induced endothelial cell death without altering NF-kB activity. 37 Thus, impairment of NF-kB may not be the sole mechanism for cell death in Tak1-deficient cells (Figure 2 ). TAK1-ROS-cIAP pathway: TNFa-induced caspase activation and subsequent cell death in Tak1-deficient cells is effectively blocked by gene deletion of Ripk1 or necrostatin-1, a pharmacologic inhibitor of RIPK1 kinase activity. 49, 58, 59 Thus, Tak1 deficiency engages RIPK1-dependent apoptosis.
However, previous studies demonstrate that extrinsic apoptosis induced by TNF family ligands is usually RIPK1-independent, 60 and kinase activity of RIPK1 is not required for caspase activation. 61 Only when cIAP is depleted by synthetic IAP antagonists (smac mimetics) or by genotoxic stress does TNFa or genotoxic stress induces RIPK1 kinase activity-dependent caspase-8 activation. 62, 63 cIAPs are responsible for K63-linked polyubiquitination of RIPK1, 64 which inhibits formation of Complex IIa (Figure 1) . 62 Interestingly, inhibition of TAK1 decreases the protein amount of cIAPs following stimulation of TNFa. 15 Thus, TAK1 is important for maintenance of cIAP protein amount, which blocks Complex IIa activation. By what mechanism is cIAP reduced in Tak1-deficient cells? It has been demonstrated that Tak1 deficiency accumulates reactive oxygen species (ROS) in response to TNFa stimulation, and ROS scavengers rescue cell death in vitro and in vivo. 15, 65, 66 One possible mechanism is that stress-induced ROS lead to degradation of cIAPs. Indeed, TNFa-induced loss of cIAPs in Tak1-deficient cells is restored by treatment with ROS scavenger, butylated hydroxyanisole. 15 Because depletion of NF-kB only marginally increases ROS under the same experimental condition as Tak1 deletion, 66 TAK1-ROS-cIAP pathway seems to act independently of TAK1-NF-kB pathway. Future studies need to identify the molecular pathways though which TAK1 modulates cellular redox status. In summary, not only activation of TAK1-IKK-NF-kB pathway but also TAK1 regulation of cellular redox system are the keys to inhibit apoptosis ( Figure 2 ). Future efforts should focus on the unidentified mechanism of TAK1-dependent alteration of cellular redox status.
TAK1 as a Necroptosis Inducer
Is TAK1 only involved in caspase-dependent cell death? Another interesting topic is the relationship between TAK1 and a different form of programmed cell death, necroptosis. When apoptosis is blocked by inhibition of caspase-8, RIPK1 and RIPK3 form Complex IIb, and they execute necroptosis, a regulated form of necrosis (Figure 1 ). RIPK3 phosphorylates mixed lineage kinase domain-like (MLKL), which induces oligomerization of MLKL resulting in plasma membrane rupture. [67] [68] [69] In human cells, it has been proposed that MLKL modulates phosphoglycerate mutase family member 5 (PGAM5) and dynamin-related protein 1 (Drp1), in which Drp1 mediates mitochondrial fragmentation, which is necessary for metabolic inactivation and induction of necroptosis. 69, 70 However, recent evidence suggests that PGAM5 and Drp1 may not be required for execution of necroptosis in murine cells. 71, 72 Nonetheless, catalytically active RIPK1 and RIPK3 are important for stable RIPK1-RIPK3 complex formation and subsequent execution of necroptotic cell death. [73] [74] [75] In this context, necrostatin-1 is widely used for improving tissue damage mediated by necroptosis induction. 61 A surprising finding regarding the regulation of RIPK1 and RIPK3 phosphorylation came from the analysis of Tab2-deficient fibroblasts, which exhibit sustained activation of TAK1 following TNFa stimulation. 38 Despite the presence of TAK1 activation, Tab2-deficient fibroblasts are killed by TNFa challenge. 49 Interestingly, while Tak1 deficiency induces caspase activation leading to apoptosis upon TNFa stimulation, Tab2 deficiency shows almost no caspase activation and results in cell death having typical necrotic features such as plasma membrane rupture. 49 Furthermore, TNFa-induced cell death in Tab2-deficient fibroblasts is almost completely rescued by Ripk3 deletion, whereas Ripk3 deletion has no effect on Tak1-deficient fibroblasts. Thus, Tab2 deletion causes necroptosis following TNFa stimulation. Two lines of evidence show that sustained TAK1 activation causes RIPK3-dependent necroptosis. One is that enforced activation of TAK1 through overexpression induces RIPK3 phosphorylation and necroptosis. The other is that additional deletion of Tak1 in Tab2-deficient fibroblasts solely induces caspasedependent apoptosis following TNFa stimulation. 49 These results collectively reveal an unexpected role of TAK1 in cell death pathways, as an inducer of necroptosis (Figure 3) . Furthermore, it has been shown that TAK1 activates RIPK3, reciprocally RIPK3 activates TAK1, and these activations are facilitated by RIPK1, which mediates TAK1-RIPK1-RIPK3 binding. 49 Thus, TAK1-RIPK1-RIPK3 is activated by a positive feedforward mechanism (Figure 3) . 49 How is TAK-RIPK1-RIPK3 assembled? Deubiquitination of RIPK1 is known to be the critical process for assembly of the necroptotic complex. 62, 76 Conversely, stabilization of RIPK1 polyubiquitin chain prevents necroptosis. 76 As discussed earlier, TAB2 is a polyubiquitin chain-binding protein and directly binds to TAK1. Hence, TAB2 tethers the binding between TAK1 and polyubiquitin chain of RIPK1 (Figure 1) . Thus, the absence of TAB2 prevents TAK1 binding to the RIPK1 polyubiquitin chain, which could lead to an alternative type of binding between TAK1 and RIPK1, resulting in activation of TAK1-RIPK1-RIPK3 assembly (Figure 3) . Alternatively, under pathologic conditions, viral inhibition of caspase promotes deubiquitination of RIPK1 and releases TAK1 from the polyubiquitin chain, which may result in the assembly of TAK1-RIPK1-RIPK3 (Figure 3 ). These possibilities should be investigated in the future studies. Although it is clear that TAK1 promotes RIPK3 activity, the importance of TAK1 in necroptosis needs to be carefully considered. Our results suggest that Tak1 deletion induces caspase-8 activation but, even if caspase-8 is inhibited, Tak1-deficient cells still undergo cell death following TNFa stimulation. 49 In line with this, combined inhibition of caspase and RIPK3 rescues TNFa-induced cell death in Tak1-deficient cells. 58, [77] [78] [79] These results suggest that, although the default pathway of cell death in Tak1-deficient cells is apoptosis, Tak1 deficiency engages an alternative RIPK1-RIPK3 necroptosis pathway if the default pathway is blocked. Interestingly, even though RIPK1 was believed to be an essential mediator of RIPK3 activation, necroptosis can still be engaged with Ripk1 deletion. 80, 81 Thus, necroptosis may be mediated through not only TAK1-RIPK1-RIPK3 complex but also through alternative complexes lacking either TAK1 or RIPK1. In summary, despite the fact that Tak1 deletion leads to hypersensitivity to TNFa-induced cell death (apoptosis), activation of TAK1 is also associated with TNFa-induced cell death (necroptosis). We will discuss later why TAK1 has such seemingly paradoxical roles in cell death.
Pathology of Tak1 Deficiency in a Variety of Tissue in Mouse Models
Deficient TAK1 signaling in mice disrupts tissue homeostasis and provokes damage to tissues that often resembles human disease pathologies, as listed in Table 1 . Epithelial cellspecific deletion of Tak1 in the epidermis or intestinal epithelium causes caspase activation and cell death leading to severe inflammation, which resembles psoriasis in the case of epidermal Tak1 deletion, and inflammatory bowel disease (IBD) in intestinal epithelium Tak1 deletion. 55, 65, 66, 82 Endothelium-specific deletion of Tak1 causes endothelial cell death and blood vessel regression around E10-11, which results in embryonic lethality. 37 Hepatocyte-specific deletion of Tak1 also causes cell death and liver injury. 57, 83 However, unlike epithelial and endothelial tissues, Tak1 deficiency in hepatocytes does not cause profound tissue damage and is not associated with immediate animal mortality. Instead, Tak1-deficient hepatocyte death induces inflammation and promotes compensatory proliferation, which eventually leads to hepatocellular carcinoma within 6 weeks. 57, 83 Hematopoietic-specific Tak1 deletion depletes hematopoietic progenitor cells, T cells and macrophages. [10] [11] [12] 58, [84] [85] [86] [87] Deletion of TNF receptor 1 (Tnfr1) largely rescues these injuries and animal mortalities, 37, 55, 57, [82] [83] [84] [85] demonstrating that TNFa is the major killer of Tak1-deficient cells in these tissues. However, some Tak1-deficient tissue injuries are still observed in Tnfr1-null background. 37, 65, 84, 85 Thus, Tak1 deficiency appears to also induce TNFa-independent cell death in vivo through mechanisms likely to be mediated by other TAK1 stimuli, including bacterial moieties and nutrient and genotoxic stress. Nonetheless, these tissue injuries are associated with caspase activation and are not rescued by Ripk3 deletion, indicating that they are primarily apoptosis. 37, 49, 55, 57, [82] [83] [84] [85] 88 We note here that the role of TAK1 in vivo may not be limited to prevention of cell death. For example, Tak1-deficient neutrophils hyperproliferate rather than dying spontaneously, leading to splenomegaly and myelomonocytic leukemia. 87, 89 Although TAK1 is known as an activator of NF-kB and p38 MAPK, Tak1 deletion in neutrophils increases activity of these downstream factors, which warrants further mechanistic analysis. Finally, we recently show that Tab2 deletion exaggerates wound-induced cell death and delays wound healing in vivo. 49 As Tab2 deletion potentially results in hyperactivation of TAK1 in dermal fibroblasts as discussed earlier and the delay in wound healing is restored by blocking necroptosis (Ripk3 deletion), TAK1 is likely to be actively involved in induction of necroptosis at least in the wound response. TAK1 may also be potentially hyperactivated when caspase is exogenously inhibited by viral infection or under yet unidentified conditions, which could be associated with pathologic necroptotic conditions such as ischemic tissue injuries and systemic inflammation.
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Functional Interaction of TAK1 and Other Cell Death Molecules In Vivo
The physiologic importance of other cell death molecules has also been extensively studied for the past several years, and Figure 3 TAK1 enhances necroptosis. RIPK3 is activated through two pathways: (1) deletion of Tab2 leads to TAK1 activation in a sustained manner following TNFa stimulation. 38 Sustained activation of TAK1 binds to and activates RIPK1 and RIPK3. TAK1 can increase phosphorylation and activation of RIPK3, and conversely, RIPK3 can increase phosphorylation and activation of TAK1. 49 However, it is still not clear whether TAK1 and RIPK3 directly phosphorylate each other; (2) when caspase-8 is blocked, RIPK1 and RIPK3 form Complex IIb to induce necroptosis. Phosphorylation of RIPK1 and RIPK3 are important for stable RIPK1-RIPK3 complex formation, [73] [74] [75] where TAK1 is also activated and facilitates RIPK3 activation, resulting in the activation of a feedforward loop between TAK1-RIPK1-RIPK3 research has revealed that programmed cell death deficiencies lead to disparate pathologies (Table 1) . Interestingly, there are many phenotypic similarities among mouse models harboring deletion of Tak1 and other cell death genes (Table 1) , suggesting in vivo functional interactions among them. The most surprising similarity is shared by mice having gene deletion of Tak1 or caspase-8. For example, either Tak1 or caspase-8 deletion in the epidermis results in psoriasis-like skin inflammation resulting in animal mortality around postnatal days 5-8 (P5-8). 82, 92 Inducible deletion of Tak1 or caspase-8 in the intestinal epithelium causes IBD-like intestinal inflammation, which is associated with loss of a specific cell type known as paneth cells. 55, 93 Similarly, epidermal-and intestinal epithelium-specific deletion of Fadd, which abrogates caspase-8 activation, causes inflammatory skin disease and IBD-like ileitis. 94, 95 Although either Tak1 or Fadd/caspase-8 deletion causes cell death, the types of cell death are different. Tak1 deletion is associated with the activation of downstream caspase-3, 55,82 whereas deletion of caspase-8 induces necroptosis in vivo, which is rescued by deletion of Ripk3. 54, 95, 96 Why are the timing and features of tissue injury so similar in mice having deletion of Tak1 or 55, 65 (Endothelium/blood vessel) Increased cell death, defective vascularization-4Lethal E10-11 37 (Liver) Increased cell death-4Hepatocellular carcinoma within 6 weeks of age 57, 83 (Hematopoietic system) Increased cell death-4Depletion of stem cells [84] [85] [86] (Myeloid) Macrophage death, splenomegaly and hyperproliferation of neutrophils 87, 89 There is a well-studied inhibitory regulation from apoptosis to necroptosis (Figure 4 , blue inhibition arrow). Thus, inhibition of caspase-8 activates necroptosis. The recent finding of TAK1 as a mediator of necroptosis raises the interesting possibility that there is an additional inhibitory regulation from necroptosis to apoptosis (Figure 4 , red inhibition arrow). Two lines of evidence support the idea that necroptosis inhibits apoptosis: (1) inhibition of RIPK3 by expressing a kinase-dead version of RIPK3 is reported to cause apoptotic cell death in vivo, which results in blood vessel abnormalities similar to endothelial-specific deletion of Tak1; 37,97 (2) deletion of Ripk1 primarily induces apoptotic cell death and tissue injury in vivo, although necroptosis is also induced. 80, 81 Thus, inhibition and/or deletion of any part of the necroptotic protein kinase cascade (TAK1, RIPK1 or RIPK3) activates apoptotic cell death in vivo. Based on these, we propose that apoptosis and necroptosis are reciprocally regulated (Figure 4) . Because of this reciprocal regulation, if one cell death pathway is inhibited, the other cell death is spontaneously activated, resulting in similar tissue injuries with the same timing in Tak1 or caspase-8-deficient tissues. What are the molecular mechanisms for these inhibitory reciprocal regulations? Caspase-8-c-FLIP heterodimer is known to be the key modulator for inhibition of necroptosis. 51, 54, 98, 99 Deletion of c-Flip causes embryonic lethality with blood vessel abnormality similar to deletion of caspase-8 or of Tak1 (Table 1) . 98 Thus far, two mechanisms for caspase-c-FLIP inhibition of necroptosis are proposed: one is that caspase-8-c-FLIP cleaves and degrades RIPK1 and RIPK3; 100, 101 and the other is that caspase-8 cleaves and degrades a deubiquitinase CYLD, resulting in stabilization of the polyubiquitin chain of RIPK1, which prevents RIPK3 activation. 76 In contrast to caspase-8-c-FLIP regulation of necroptosis, the regulation of apoptosis by necroptosis signaling proteins is just beginning to be investigated. It has thus far been clear that the necroptosis-mediated inhibition of apoptosis possesses unique and complex features. Only manipulation of TAK1 induces predictable outcomes, in which both deletion of Tak1 gene and inhibition of TAK1 by a selective inhibitor, 5Z-7-oxozeaenol, 102 activates apoptotic cell death. 103, 104 In contrast, it is very puzzling that inhibition and gene deletion of RIPK1 and RIPK3 result in different phenotypes. Inhibition of RIPK3 kinase activity activates caspases and tissue injury, 97 whereas deletion of Ripk3 does not cause any abnormality. 105 Conversely, inhibition of RIPK1 by knocking-in a kinase-dead version of RIPK1 or necrostatin-1 treatment does not cause any tissue injury, 47, 97 whereas deletion of Ripk1 causes cell death and systemic inflammation in vivo. 80, 81 It should be of immediate interest to elucidate the molecular mechanism of how TAK1, RIPK1 and RIPK3 interplay to inhibit apoptosis pathways.
Conclusions
It is clear that TAK1 is a key molecular component in the determination of cell fate. Historically, the role of TAK1 has been considered prosurvival, first characterized by antiapoptotic proteins downstream of NF-kB and cell growth and proliferation downstream of MAPK pathways. We now know that TAK1 engages multiple downstream cell death pathways in response to a rich diversity of environmental and endogenous stimuli. As an inhibitor of caspase activation, TAK1 prevents TNFa-mediated apoptotic cell death through modulation of the RIPK1-FADD-caspase-8 pathway. An NFkB-independent cell survival pathway downstream of TAK1 has just begun to be explored, with interesting possibilities involving ROS and cIAPs. However, when caspase-8 is blocked or TAK1 activation is sustained, TAK1 acts as a cell death inducer through necroptosis activation. Similarly, the mechanism by which TAK1 promotes RIPK1/RIPK3-dependent necroptosis warrants further study. Enforcing cell death pathways can be used therapeutically to kill undesired cells such as tumor cells. Inhibition of TAK1 induces stressdependent apoptosis. Furthermore, although some tumor cells are known to gain antiapoptotic functions, inhibition of TAK1 alone is effective as inhibition of both TAK1 and caspase still induces cell death. Thus, inhibition of TAK1 is one of the most promising approaches to therapeutic cell killing, as proposed also in recent cancer studies. 102, 105 This further emphasizes the importance of studies elucidating the regulatory mechanisms of TAK1 in the cell death network.
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